Juvenile-onset lupus relapsed far more often; late-onset reached remission but carried more deaths

Design

Retrospective cohort

Population

289 patients with SLE (96 juvenile-, 96 adult-, 97 late-onset)

Primary outcome

DORIS remission, LLDAS and relapse

Effect

Late onset: remission HR 2.8 (1.9–4.0), LLDAS HR 2.4 (1.7–3.4); relapse 87.5% vs 66.7% vs 24.7%

This retrospective cohort compared 289 patients meeting 2019 EULAR/ACR criteria for lupus, grouped by age at onset: juvenile (under 18; 96), adult (18 to 49; 96) and late (50 or over; 97).

Juvenile-onset patients had higher disease activity at diagnosis and more neuropsychiatric disease; adults had more mucocutaneous and renal disease. Late onset independently predicted reaching DORIS remission (HR 2.8, 95% CI 1.9 to 4.0) and low disease activity (HR 2.4, 1.7 to 3.4). Relapse occurred in 87.5% of juvenile, 66.7% of adult and 24.7% of late-onset patients; juvenile onset (HR 2.1) and constitutional features at onset (HR 1.6) predicted relapse. Mortality was higher in late-onset lupus, mainly from infection.

Age at onset changes the plan. Children and adolescents need tighter follow-up and a clear transition to adult care; older patients may reach remission but need careful infection prevention and, as in all lupus, minimal glucocorticoid exposure.

• Expect frequent flares in juvenile-onset lupus and plan closer monitoring through transition to adult care.
• Screen juvenile-onset patients for neuropsychiatric involvement.
• In late-onset lupus, prioritise vaccination and infection prevention and, as in all lupus, minimise glucocorticoid exposure.
• Use DORIS remission and LLDAS as explicit treatment targets at every review.
• Treat constitutional symptoms at onset as a marker of higher relapse risk.

Why it matters

The same diagnosis carries very different risks — relapse in the young, infection in the old — that should shape the plan.

Don't overread it

A retrospective cohort; differences in treatment across age groups could explain part of the pattern.

The statistics, in plain English

A hazard ratio of 2.8 for remission means late-onset patients reached remission at nearly three times the rate of others at any point in follow-up. Relapse proportions are crude, not adjusted for how long each group was followed.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.